Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: W.B. Saunders Country of Publication: United States NLM ID: 8110075 Publication Model: Print Cited Medium: Internet ISSN: 1523-6838 (Electronic) Linking ISSN: 02726386 NLM ISO Abbreviation: Am J Kidney Dis Subsets: MEDLINE
- Publication Information:
Publication: Philadelphia Pa : W.B. Saunders
Original Publication: New York, N.Y. : Grune & Stratton, c1981-
- Subject Terms:
- Abstract:
Imatinib mesylate (Gleevec, Glivec; Novartis, Basel, Switzerland) is a specific tyrosine kinase inhibitor that has become the gold-standard treatment for patients with chronic myeloid leukemia. Several tyrosine kinases inhibited by imatinib are expressed in the kidney, and although the drug is usually well tolerated, several cases of acute renal failure were reported. We describe for the first time a case of a patient treated by imatinib for chronic myeloid leukemia who developed partial Fanconi syndrome with mild renal failure, which leads to a discussion of the pathophysiological characteristics of imatinib-induced renal toxicity. Patients on long-term imatinib treatment should be monitored for renal failure, as well as proximal tubule dysfunction, including hypophosphatemia.
- Accession Number:
0 (Antineoplastic Agents)
0 (Benzamides)
0 (Phosphates)
0 (Piperazines)
0 (Protein Kinase Inhibitors)
0 (Pyrimidines)
8A1O1M485B (Imatinib Mesylate)
EC 2.7.10.1 (Protein-Tyrosine Kinases)
- Publication Date:
Date Created: 20080125 Date Completed: 20080204 Latest Revision: 20151119
- Publication Date:
20231215
- Accession Number:
10.1053/j.ajkd.2007.10.039
- Accession Number:
18215707
No Comments.